Familial cancer syndrome

Beth T. Harrison, Rodolfo Montironi, Antonio Lopez-Beltran, Michelle P. Elieff, Liang Cheng

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Familial cancer syndromes arise from the inheritance of pathogenic germline mutations that increase the risk of cancer. Most commonly, these syndromes are associated with tumor suppressor genes according to Knudson's two-hit hypothesis, in which a mutation carrier develops cancer after somatic inactivation of the second allele. Well-known syndromes include retinoblastoma, hereditary breast and ovarian cancer syndrome (due to mutations in BRCA1 and BRCA2), Lynch syndrome (due to microsatellite instability), familial adenomatous polyposis, and multiple endocrine neoplasia types 1 and 2 among many others. Genetic alterations range from cytogenetically visible ones to submicroscopic ones requiring molecular detection methods. Genetic testing has rapidly evolved in recent years. Due to advancements in sequencing platforms, full gene sequencing is often employed as the first step in genetic testing, with its sensitivity enhanced by additional molecular approaches. It is predicted that implementation, validation, and interpretation of sequencing-based assays in the diagnosis of both sporadic and inherited diseases will fall increasingly into the realm of the clinical laboratorian. In this chapter, we review the clinical, pathologic, and molecular genetic features of the major hereditary cancer syndromes and the genetic testing strategies for each one.

Original languageEnglish
Title of host publicationMolecular Genetic Pathology: Second Edition
PublisherSpringer New York
Pages607-643
Number of pages37
ISBN (Print)9781461448006, 1461447992, 9781461447993
DOIs
StatePublished - Mar 1 2014

Fingerprint

Genetic Testing
Hereditary Breast and Ovarian Cancer Syndrome
Hereditary Neoplastic Syndromes
Multiple Endocrine Neoplasia Type 2a
Multiple Endocrine Neoplasia Type 1
Hereditary Nonpolyposis Colorectal Neoplasms
Neoplasms
Microsatellite Instability
Mutation
Adenomatous Polyposis Coli
Retinoblastoma
Germ-Line Mutation
Tumor Suppressor Genes
Molecular Biology
Alleles
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Harrison, B. T., Montironi, R., Lopez-Beltran, A., Elieff, M. P., & Cheng, L. (2014). Familial cancer syndrome. In Molecular Genetic Pathology: Second Edition (pp. 607-643). Springer New York. https://doi.org/10.1007/978-1-4614-4800-6-23

Familial cancer syndrome. / Harrison, Beth T.; Montironi, Rodolfo; Lopez-Beltran, Antonio; Elieff, Michelle P.; Cheng, Liang.

Molecular Genetic Pathology: Second Edition. Springer New York, 2014. p. 607-643.

Research output: Chapter in Book/Report/Conference proceedingChapter

Harrison, BT, Montironi, R, Lopez-Beltran, A, Elieff, MP & Cheng, L 2014, Familial cancer syndrome. in Molecular Genetic Pathology: Second Edition. Springer New York, pp. 607-643. https://doi.org/10.1007/978-1-4614-4800-6-23
Harrison BT, Montironi R, Lopez-Beltran A, Elieff MP, Cheng L. Familial cancer syndrome. In Molecular Genetic Pathology: Second Edition. Springer New York. 2014. p. 607-643 https://doi.org/10.1007/978-1-4614-4800-6-23
Harrison, Beth T. ; Montironi, Rodolfo ; Lopez-Beltran, Antonio ; Elieff, Michelle P. ; Cheng, Liang. / Familial cancer syndrome. Molecular Genetic Pathology: Second Edition. Springer New York, 2014. pp. 607-643
@inbook{0625910940694948a763424ceda66ddf,
title = "Familial cancer syndrome",
abstract = "Familial cancer syndromes arise from the inheritance of pathogenic germline mutations that increase the risk of cancer. Most commonly, these syndromes are associated with tumor suppressor genes according to Knudson's two-hit hypothesis, in which a mutation carrier develops cancer after somatic inactivation of the second allele. Well-known syndromes include retinoblastoma, hereditary breast and ovarian cancer syndrome (due to mutations in BRCA1 and BRCA2), Lynch syndrome (due to microsatellite instability), familial adenomatous polyposis, and multiple endocrine neoplasia types 1 and 2 among many others. Genetic alterations range from cytogenetically visible ones to submicroscopic ones requiring molecular detection methods. Genetic testing has rapidly evolved in recent years. Due to advancements in sequencing platforms, full gene sequencing is often employed as the first step in genetic testing, with its sensitivity enhanced by additional molecular approaches. It is predicted that implementation, validation, and interpretation of sequencing-based assays in the diagnosis of both sporadic and inherited diseases will fall increasingly into the realm of the clinical laboratorian. In this chapter, we review the clinical, pathologic, and molecular genetic features of the major hereditary cancer syndromes and the genetic testing strategies for each one.",
author = "Harrison, {Beth T.} and Rodolfo Montironi and Antonio Lopez-Beltran and Elieff, {Michelle P.} and Liang Cheng",
year = "2014",
month = "3",
day = "1",
doi = "10.1007/978-1-4614-4800-6-23",
language = "English",
isbn = "9781461448006",
pages = "607--643",
booktitle = "Molecular Genetic Pathology: Second Edition",
publisher = "Springer New York",

}

TY - CHAP

T1 - Familial cancer syndrome

AU - Harrison, Beth T.

AU - Montironi, Rodolfo

AU - Lopez-Beltran, Antonio

AU - Elieff, Michelle P.

AU - Cheng, Liang

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Familial cancer syndromes arise from the inheritance of pathogenic germline mutations that increase the risk of cancer. Most commonly, these syndromes are associated with tumor suppressor genes according to Knudson's two-hit hypothesis, in which a mutation carrier develops cancer after somatic inactivation of the second allele. Well-known syndromes include retinoblastoma, hereditary breast and ovarian cancer syndrome (due to mutations in BRCA1 and BRCA2), Lynch syndrome (due to microsatellite instability), familial adenomatous polyposis, and multiple endocrine neoplasia types 1 and 2 among many others. Genetic alterations range from cytogenetically visible ones to submicroscopic ones requiring molecular detection methods. Genetic testing has rapidly evolved in recent years. Due to advancements in sequencing platforms, full gene sequencing is often employed as the first step in genetic testing, with its sensitivity enhanced by additional molecular approaches. It is predicted that implementation, validation, and interpretation of sequencing-based assays in the diagnosis of both sporadic and inherited diseases will fall increasingly into the realm of the clinical laboratorian. In this chapter, we review the clinical, pathologic, and molecular genetic features of the major hereditary cancer syndromes and the genetic testing strategies for each one.

AB - Familial cancer syndromes arise from the inheritance of pathogenic germline mutations that increase the risk of cancer. Most commonly, these syndromes are associated with tumor suppressor genes according to Knudson's two-hit hypothesis, in which a mutation carrier develops cancer after somatic inactivation of the second allele. Well-known syndromes include retinoblastoma, hereditary breast and ovarian cancer syndrome (due to mutations in BRCA1 and BRCA2), Lynch syndrome (due to microsatellite instability), familial adenomatous polyposis, and multiple endocrine neoplasia types 1 and 2 among many others. Genetic alterations range from cytogenetically visible ones to submicroscopic ones requiring molecular detection methods. Genetic testing has rapidly evolved in recent years. Due to advancements in sequencing platforms, full gene sequencing is often employed as the first step in genetic testing, with its sensitivity enhanced by additional molecular approaches. It is predicted that implementation, validation, and interpretation of sequencing-based assays in the diagnosis of both sporadic and inherited diseases will fall increasingly into the realm of the clinical laboratorian. In this chapter, we review the clinical, pathologic, and molecular genetic features of the major hereditary cancer syndromes and the genetic testing strategies for each one.

UR - http://www.scopus.com/inward/record.url?scp=84929930644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929930644&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-4800-6-23

DO - 10.1007/978-1-4614-4800-6-23

M3 - Chapter

AN - SCOPUS:84929930644

SN - 9781461448006

SN - 1461447992

SN - 9781461447993

SP - 607

EP - 643

BT - Molecular Genetic Pathology: Second Edition

PB - Springer New York

ER -